StreetInsider.com News Articles

Form 8-K TNF Pharmaceuticals, For: Mar 06

Mon, 10 Mar 2025 17:00:00 -0400

si-local-file:///var/storage/secattach/20250310/24478906.html

Form 8-K TNF Pharmaceuticals, For: Mar 06

Mon, 10 Mar 2025 17:00:00 -0400

si-local-file:///var/storage/secattach/20250310/24478906.html

TNF Pharmaceuticals (TNFA) Announces Positive Clinical Data Supporting Clinical Trial Expansion

Wed, 15 Jan 2025 09:15:32 -0400

TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNFA” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel oral therapies for autoimmune and inflammatory conditions, today announced that it has achieved a key safety data milestone supporting expanded and longer-term clinical studies of its novel TNF-alpha (TNF-α) inhibitor drug, isomyosamine, in multiple indications.

The Company successfully completed an FDA-recommended study of isomyosamine that demonstrated clinical safety throughout 13 weeks of treatment at all dose levels evaluated.

“Positive data from this milestone study confirms isomyosamine’s historically strong safety profile and enables us to extend the duration of future clinical trials,” said Mitchell

TNF Pharmaceuticals (TNFA) Announces Positive Clinical Data Supporting Clinical Trial Expansion

Wed, 15 Jan 2025 09:15:32 -0400

The Company successfully completed an FDA-recommended study of isomyosamine that demonstrated clinical safety throughout 13 weeks of treatment at all dose levels evaluated.

“Positive data from this milestone study confirms isomyosamine’s historically strong safety profile and enables us to extend the duration of future clinical trials,” said Mitchell

TNF Pharmaceuticals (TNFA) Announces Positive Clinical Data Supporting Clinical Trial Expansion

Wed, 15 Jan 2025 09:15:32 -0400

The Company successfully completed an FDA-recommended study of isomyosamine that demonstrated clinical safety throughout 13 weeks of treatment at all dose levels evaluated.

“Positive data from this milestone study confirms isomyosamine’s historically strong safety profile and enables us to extend the duration of future clinical trials,” said Mitchell

TNF Pharmaceuticals (TNFA) Announces Positive Clinical Data Supporting Clinical Trial Expansion

Wed, 15 Jan 2025 09:15:32 -0400

The Company successfully completed an FDA-recommended study of isomyosamine that demonstrated clinical safety throughout 13 weeks of treatment at all dose levels evaluated.

“Positive data from this milestone study confirms isomyosamine’s historically strong safety profile and enables us to extend the duration of future clinical trials,” said Mitchell

TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion

Wed, 15 Jan 2025 09:15:00 -0400

Set to begin larger Phase 2b study in sarcopenia and new trial in GLP-1-induced sarcopenia and frailty

Transformative potential for novel TNF-alpha inhibitor drug:

Estimated $40 billion TNF inhibitor market and $50 billion GLP-1 agonist market

BALTIMORE--(BUSINESS WIRE)-- TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNFA” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel oral therapies for autoimmune and inflammatory conditions, today announced that it has achieved a key safety data milestone supporting expanded and longer-term clinical studies of its novel TNF-alpha (TNF-α) inhibitor drug, isomyosamine, in multiple indications.

The Company successfully completed an FDA-recommended study of

TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion

Wed, 15 Jan 2025 09:15:00 -0400

Set to begin larger Phase 2b study in sarcopenia and new trial in GLP-1-induced sarcopenia and frailty

Transformative potential for novel TNF-alpha inhibitor drug:

Estimated $40 billion TNF inhibitor market and $50 billion GLP-1 agonist market

The Company successfully completed an FDA-recommended study of

TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion

Wed, 15 Jan 2025 09:15:00 -0400

Set to begin larger Phase 2b study in sarcopenia and new trial in GLP-1-induced sarcopenia and frailty

Transformative potential for novel TNF-alpha inhibitor drug:

Estimated $40 billion TNF inhibitor market and $50 billion GLP-1 agonist market

The Company successfully completed an FDA-recommended study of

TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion

Wed, 15 Jan 2025 09:15:00 -0400

Set to begin larger Phase 2b study in sarcopenia and new trial in GLP-1-induced sarcopenia and frailty

Transformative potential for novel TNF-alpha inhibitor drug:

Estimated $40 billion TNF inhibitor market and $50 billion GLP-1 agonist market

The Company successfully completed an FDA-recommended study of

TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion

Wed, 15 Jan 2025 09:15:00 -0400

Set to begin larger Phase 2b study in sarcopenia and new trial in GLP-1-induced sarcopenia and frailty

Transformative potential for novel TNF-alpha inhibitor drug:

Estimated $40 billion TNF inhibitor market and $50 billion GLP-1 agonist market

The Company successfully completed an FDA-recommended study of

TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion

Wed, 15 Jan 2025 09:15:00 -0400

Set to begin larger Phase 2b study in sarcopenia and new trial in GLP-1-induced sarcopenia and frailty

Transformative potential for novel TNF-alpha inhibitor drug:

Estimated $40 billion TNF inhibitor market and $50 billion GLP-1 agonist market

The Company successfully completed an FDA-recommended study of

TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion

Wed, 15 Jan 2025 09:15:00 -0400

Set to begin larger Phase 2b study in sarcopenia and new trial in GLP-1-induced sarcopenia and frailty

Transformative potential for novel TNF-alpha inhibitor drug:

Estimated $40 billion TNF inhibitor market and $50 billion GLP-1 agonist market

The Company successfully completed an FDA-recommended study of

TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion

Wed, 15 Jan 2025 09:15:00 -0400

Set to begin larger Phase 2b study in sarcopenia and new trial in GLP-1-induced sarcopenia and frailty

Transformative potential for novel TNF-alpha inhibitor drug:

Estimated $40 billion TNF inhibitor market and $50 billion GLP-1 agonist market

The Company successfully completed an FDA-recommended study of

TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs

Thu, 19 Dec 2024 09:15:00 -0400

Fully funded study to evaluate Wegovy and Ozempic patients at risk for increased inflammation associated with sarcopenic muscle deterioration